Zephyr AI’s Artificial Intelligence and Machine Learning (AI/ML) models and software in development will leverage real-world data to improve outcomes in diabetes patients.
Precision medicine technology trailblazer Zephyr AI, Inc. (“Zephyr AI”) has launched a partnership to further develop its artificial intelligence (AI)-enabled Insights product—which tailors and transforms care for chronically ill patients—with MedStar Health, the leading healthcare provider in Maryland and the Washington, D.C., region. Initially focused on type 2 diabetes (T2D), the partnership will leverage MedStar Health’s T2D de-identified data sets and patient management expertise to refine Zephyr AI’s predictive analytics Insights product.
“It is a privilege to train our Insights productwith MedStar Health’s data and to partner with MedStar Health’s world-class clinicians,” said Grant Verstandig, Zephyr AI Co-Founder and Executive Chairman, and CEO and a Founding Partner at Red Cell Partners. “We are laser-focused on delivering results that improve the timeliness of T2D interventions and decrease devastating adverse health outcomes commonly associated with the chronic condition, such as end-stage chronic kidney disease, dialysis, foot ulcers, and amputations.”
“Our partnership with Zephyr AI is a breakthrough opportunity to develop innovative artificial intelligence and machine learning capabilities, starting with type 2 diabetes, to benefit our patients and our providers,” said MedStar Health Executive Vice President and Chief Medical Officer Stephen R.T. Evans, MD. “Together, Zephyr AI and MedStar Health can develop technology that brings the promise of precision medicine to chronic diseases and that complements our existing programs to improve outcomes and reduce costs for people with diabetes.”
“While there have always been well-known population risk factors associated with adverse outcomes in patients diagnosed with T2D, this partnership will allow Zephyr AI to train our revolutionary machine learning models on one of the most robust T2D data sets in the world. The combination of our team’s world-class AI with MedStar Health’s data and expertise dramatically increases our collective prediction accuracy and will help both partners shift from a population-level predictive capability to an individual-level predictive capability,” said Zephyr AI CEO David L. Morgan II. “This relationship means that we can leverage real-world data from a renowned health system that has one of the most advanced, innovative, and successful T2D programs in the U.S. Ultimately, we believe we can help patients better manage their diabetes by developing predictive tools for clinicians.”
This announcement exemplifies Zephyr AI’s leadership in building novel, transparent AI to improve patients’ lives by addressing unmet precision medicine needs across the full spectrum of care—from prevention to treatment. Zephyr AI makes this possible through high-impact collaborations with partners like MedStar Health, a nationally-recognized, $6.7 billion not-for-profit regional healthcare system that most recently supported more than 5.9 million in combined outpatient visits and inpatient admissions in a year.
According to the Centers for Disease Control and Prevention (CDC), more than 37 million Americans have diabetes—about one in every 10 people. Approximately 90-95% of them have type 2 diabetes, a long-term condition that can lead to circulatory, nervous, and immune disorders that seriously impact the quality of life. Diabetes is also estimated to account for nearly one in seven U.S. healthcare dollars, as reported by the American Diabetes Association.
Visit AITechPark for cutting-edge Tech Trends around AI, ML, Cybersecurity, along with AITech News, and timely updates from industry professionals!
